Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.
The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.
If you are looking for guidance based on this study's results: IFM_05-May 2022
Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team.
To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods. Due to the risk of secondary cancers identified
Lenalidomide was the primary drug used for maintenance in this study. Key Findings:
One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations To determine if continuous low-dose chemotherapy after a
Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI
